Abstract
Objective
Method
Results
Conclusion
Résumé
Objectif
Méthodologie
Résultats
Conclusion
Keywords
INTRODUCTION
METHODS
Study Design and Participants
Data Analyses
RESULTS
Prevalence

Parameter | Women with DxE (n = 2004) | Women without DxE (n = 26 528) |
---|---|---|
Average age, years, mean ± SD | 35.5 ± 8.1 | 33.6 ± 9.2 |
Age group, years, % | ||
18–29 | 25.6 | 37.2 |
30–34 | 19.5 | 16.0 |
35–39 | 21.4 | 15.3 |
40–44 | 16.0 | 15.5 |
45–49 | 17.6 | 16.1 |
Average age at diagnosis, years, mean ± SD | 27.9 ± 8.1 | — |
Age group at diagnosis, years, % | ||
<18 | 8.4 | — |
18–29 | 47.5 | — |
30–34 | 25.9 | — |
35–39 | 11.8 | — |
40–44 | 5.3 | — |
45–49 | 1.0 | — |
Ethnicity, % | ||
White | 88.8 | 78.0 |
Black | 1.0 | 3.1 |
Hispanic | 1.0 | 1.1 |
Other | 8.4 | 16.3 |
When patients began experiencing symptoms, % | ||
Before diagnosis | 84.1 | — |
At time of diagnosis | 3.7 | — |
After diagnosis | 6.0 | — |
Unsure | 6.2 | — |
Had hysterectomy, % | 29.4 | 3.7 |
Canadian province, % | ||
Ontario | 37.5 | 39.1 |
Québec | 18.6 | 24.0 |
British Columbia | 16.7 | 12.7 |
Alberta | 15.3 | 10.4 |
Manitoba | 3.3 | 3.5 |
Nova Scotia | 3.2 | 2.8 |
Saskatchewan | 2.5 | 3.0 |
Newfoundland and Labrador | 1.4 | 1.5 |
New Brunswick | 1.1 | 2.4 |
Prince Edward Island | 0.3 | 0.4 |
Northwest Territories | 0 | 0.1 |
Nunavut | 0 | 0.1 |
Yukon | 0 | 0.1 |
Symptom Burden
Symptom | Women with DxE (n = 2 004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) |
---|---|---|---|
Menstrual pelvic pain or cramping | 70.3 | 50.7 | 2.4 (2.1–2.6) |
Non-menstrual pelvic pain or cramping | 49.5 | 18.7 | 4.4 (4.0–4.9) |
Dyspareunia | 52.5 | 28.0 | 3.0 (2.7–3.3) |
Fatigue, weariness, or anemia | 67.4 | 56.3 | 1.6 (1.5–1.8) |
Heavy menstrual bleeding | 68.7 | 47.1 | 2.5 (2.2–2.7) |
Excessive or irregular bleeding (e.g., spotting between periods) | 47.6 | 25.7 | 2.7 (2.4–2.9) |
Passage of clots | 43.5 | 23.5 | 2.4 (2.2–2.6) |
Irregular periods (timing and/or duration) | 61.4 | 47.6 | 1.8 (1.7–2.0) |
Pelvic pressure | 32.7 | 11.3 | 3.9 (3.5–4.3) |
Lower back pain | 66.5 | 63.4 | 1.1 (1.0–1.3) |
General abdominal pain | 52.2 | 33.7 | 2.2 (2.0–2.5) |
Constipation, bloating, or diarrhea | 66.5 | 62.6 | 1.2 (1.1–1.3) |
Difficulty having bowel movement | 47.6 | 36.1 | 1.6 (1.5–1.8) |
Frequent urination or urinary urgency | 40.5 | 27.1 | 1.8 (1.7–2.0) |
Infertility | 22.3 | 6.3 | 4.1 (3.6–4.6) |
Depressed feelings or mood swings | 64.2 | 62.8 | 1.1 (1.0–1.2) |
Dizziness during period | 44.6 | 26.3 | 2.5 (2.2–2.7) |
Anxiety or stress | 74.1 | 73.8 | 1.1 (1.0–1.2) |
Complications during pregnancy and labour | 25.3 | 14.1 | 1.9 (1.7–2.1) |
Currently experiencing symptoms | Currently experiencing severe symptoms | |||||
---|---|---|---|---|---|---|
Symptom | Women with DxE (n = 2004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) | Women with DxE (n = 2004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) |
Menstrual pelvic pain or cramping | 54.0 | 39.3 | 1.9 (1.7–2.1) | 37.3 | 17.6 | 2.9 (2.5–3.3) |
Non-menstrual pelvic pain or cramping | 39.4 | 14.2 | 4.2 (3.8–4.6) | 25.3 | 9.3 | 3.4 (2.8–4.2) |
Dyspareunia | 38.3 | 17.7 | 3.1 (2.8–3.4) | 17.3 | 9.2 | 2.1 (1.7–2.6) |
Heavy menstrual bleeding | 48.0 | 33.3 | 2.0 (1.8–2.2) | 38.3 | 22.8 | 2.1 (1.8–2.4) |
Excessive or irregular bleeding (e.g., spotting between periods) | 31.8 | 15.6 | 2.6 (2.4–2.9) | 24.8 | 12.3 | 2.3 (1.9–2.9) |
Passage of clots | 26.4 | 14.9 | 2.0 (1.8–2.2) | 22.7 | 11.3 | 2.3 (1.8–2.8) |
Irregular periods (timing and/or duration) | 41.7 | 31.3 | 1.7 (1.5–1.8) | 30.0 | 17.6 | 2.1 (1.8–2.4) |
Pelvic pressure | 27.6 | 8.7 | 4.1 (3.7–4.6) | 20.2 | 7.9 | 3.0 (2.3–3.8) |
Lower back pain | 61.6 | 56.2 | 1.2 (1.1–1.4) | 26.9 | 16.9 | 1.8 (1.6–2.1) |
General abdominal pain | 44.9 | 27.4 | 2.3 (2.1–2.5) | 22.4 | 9.1 | 3.0 (2.5–3.6) |
Constipation, bloating, or diarrhea | 60.1 | 52.2 | 1.4 (1.3–1.5) | 18.5 | 10.2 | 2.0 (1.7–2.4) |
Difficulty having bowel movement | 41.8 | 28.8 | 1.8 (1.6–2.0) | 16.8 | 10.8 | 1.7 (1.4–2.0) |
Fatigue, weariness, or anemia | 61.7 | 51.7 | 1.5 (1.4–1.7) | 31.7 | 20.0 | 1.9 (1.7–2.2) |
Frequent urination or urinary urgency | 34.8 | 20.7 | 2.0 (1.8–2.2) | 23.5 | 15.2 | 1.7 (1.4–2.1) |
Infertility | 15.0 | 3.8 | 4.4 (3.8–5.1) | 55.3 | 54.4 | 1.0 (0.8–1.3) |
Depressed feelings or mood swings | 60.4 | 55.8 | 1.3 (1.2–1.4) | 27.7 | 22.7 | 1.5 (1.3–1.7) |
Dizziness during period | 32.3 | 19.3 | 2.2 (2.0–2.4) | 19.3 | 8.8 | 2.7 (2.1–3.3) |
Anxiety or stress | 70.9 | 69.5 | 1.1 (1.0–1.3) | 31.0 | 26.8 | 1.4 (1.2–1.5) |
Complications during pregnancy and labour | 10.0 | 3.9 | 2.6 (2.2–3.1) | 43.8 | 34.6 | 1.5 (1.1–2.0) |
Not at all bothersome | Somewhat bothersome | Extremely bothersome | |||||||
---|---|---|---|---|---|---|---|---|---|
Symptom | Women with DxE (n = 2004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) | Women with DxE (n = 2004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) | Women with DxE (n = 2004), % | Women without DxE (n = 26 528), % | Odds ratio (95% CI) |
Menstrual pelvic pain or cramping | 11.9 | 18.1 | 0.6 (0.5–0.7) | 47.1 | 57.2 | 0.7 (0.6–0.7) | 41.0 | 24.7 | 2.3 (2.0–2.6) |
Non-menstrual pelvic pain or cramping | 12.4 | 23.4 | 0.5 (0.4–0.6) | 53.6 | 59.4 | 0.8 (0.7–0.9) | 34.0 | 17.2 | 2.6 (2.2–3.1) |
Dyspareunia | 13.3 | 20.6 | 0.6 (0.5–0.7) | 50.2 | 57.0 | 0.7 (0.6–0.9) | 36.5 | 22.4 | 2.1 (1.8–2.4) |
Heavy menstrual bleeding | 8.6 | 15.7 | 0.5 (0.4–0.6) | 43.9 | 49.0 | 0.8 (0.7–0.9) | 47.5 | 35.3 | 1.7 (1.4–1.9) |
Excessive or irregular bleeding (e.g., spotting between periods) | 15.7 | 24.8 | 0.6 (0.5–0.7) | 47.1 | 50.8 | 0.9 (0.7–1.0) | 37.2 | 24.5 | 1.8 (1.5–2.2) |
Passage of clots | 30.9 | 44.1 | 0.6 (0.5–0.7) | 44.8 | 41.3 | 1.1 (0.9–1.4) | 24.3 | 14.6 | 1.8 (1.5–2.3) |
Irregular periods (timing and/or duration) | 18.1 | 29.4 | 0.5 (0.4–0.6) | 46.5 | 50.5 | 0.9 (0.7–1.0) | 35.4 | 20.0 | 2.2 (1.9–2.6) |
Pelvic pressure | 10.9 | 26.2 | 0.3 (0.3–0.5) | 61.1 | 59.2 | 1.1 (0.9–1.3) | 28.0 | 14.6 | 2.3 (1.8–2.9) |
Lower back pain | 11.2 | 17.4 | 0.6 (0.5–0.7) | 51.7 | 57.0 | 0.8 (0.7–0.9) | 37.1 | 25.7 | 1.8 (1.6–2.0) |
General abdominal pain | 10.9 | 22.3 | 0.4 (0.3–0.5) | 57.8 | 61.7 | 0.8 (0.7–1.0) | 31.3 | 16.1 | 2.6 (2.2–3.0) |
Constipation, bloating, or diarrhea | 13.1 | 20.4 | 0.6 (0.5–0.7) | 58.0 | 59.9 | 0.9 (0.8–1.0) | 28.9 | 19.7 | 1.7 (1.5–2.0) |
Difficulty having bowel movement | 16.0 | 20.6 | 0.7 (0.6–0.9) | 54.3 | 58.8 | 0.8 (0.7–0.9) | 29.7 | 20.6 | 1.7 (1.4–2.0) |
Fatigue, weariness, or anemia | 8.3 | 13.6 | 0.6 (0.5–0.7) | 51.8 | 56.3 | 0.8 (0.7–0.9) | 39.8 | 30.2 | 1.6 (1.4–1.8) |
Frequent urination or urinary urgency | 11.6 | 15.7 | 0.7 (0.6–0.9) | 52.5 | 56.7 | 0.8 (0.7–1.0) | 35.9 | 27.7 | 1.5 (1.2–1.7) |
Infertility | 18.6 | 21.5 | 0.8 (0.6–1.2) | 31.6 | 24.8 | 1.4 (1.1–1.9) | 49.8 | 53.7 | 0.9 (0.7–1.1) |
Depressed feelings or mood swings | 9.6 | 10.6 | 0.8 (0.7–1.0) | 44.4 | 50.8 | 0.7 (0.6–0.8) | 46.0 | 38.7 | 1.5 (1.3–1.7) |
Dizziness during period | 15.6 | 20.4 | 0.7 (0.6–0.9) | 55.0 | 60.9 | 0.8 (0.7–0.9) | 29.4 | 18.7 | 1.9 (1.5–2.2) |
Anxiety or stress | 8.6 | 11.6 | 0.7 (0.5–0.8) | 45.5 | 49.4 | 0.8 (0.7–0.9) | 45.9 | 38.9 | 1.5 (1.3–1.7) |
Complications during pregnancy and labour | 14.5 | 26.7 | 0.5 (0.3–0.7) | 40.5 | 32.9 | 1.4 (1.0–1.9) | 45.0 | 40.4 | 1.2 (0.9–1.6) |
Diagnostic Experience
DISCUSSION
CONCLUSION
REFERENCES
- Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis.Hum Reprod Update. 2013; 19: 406-418
- ESHRE guideline for the diagnosis and treatment of endometriosis.Hum Reprod. 2005; 20: 2698-2704
- Endometriosis and infertility.J Assist Reprod Genet. 2010; 27: 441-447
- The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study.J Psychosom Obstet Gynaecol. 2017; 38: 238-248
- The social and psychological impact of endometriosis on women's lives: a critical narrative review.Hum Reprod Update. 2013; 19: 625-639
- Epidemiology of endometriosis-associated infertility.J Reprod Med. 1989; 34: 41-46
- Epidemiology of endometriosis.Obstet Gynecol Clin North Am. 1997; 24: 235-258
- Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women.Fertil Steril. 2006; 86: 1584-1595
- Prevalence of endometriosis in asymptomatic women.J Reprod Med. 1991; 36: 513-515
- Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women.Gynecol Obstet Invest. 2017; 82: 453-461
- Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study–Part 1.BJOG. 2008; 115: 1382-1391
- Female perspectives on endometriosis: findings from the Uterine Bleeding and Pain Women's Research Study.J Endometr. 2011; 3: 73-85
- What makes a good case-control study? Design issues for complex traits such as endometriosis.Hum Reprod. 2002; 17: 1415-1423
- Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study–Part 2.BJOG. 2008; 115: 1392-1396
- Society of Obstetricians and Gynaecologists of Canada. Endometriosis: diagnosis and management.J Obstet Gynaecol Can. 2010; 32: S1-32
- Factors associated with time to endometriosis diagnosis in the United States.J Womens Health (Larchmt). 2017; 26: 788-797
- Characteristics of women with endometriosis from the USA and Puerto Rico.J Endometr Pelvic Pain Disord. 2015; 7: 129-135
- Impact of endometriosis on women's lives: a qualitative study.BMC Womens Health. 2014; 14: 123
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries.Fertil Steril. 2011; 96 (e8): 366-373
- What's the delay? A qualitative study of women's experiences of reaching a diagnosis of endometriosis.Fertil Steril. 2006; 86: 1296-1301
- Economic burden of surgically confirmed endometriosis in Canada.J Obstet Gynaecol Can. 2011; 33: 830-837
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres.Hum Reprod. 2012; 27: 1292-1299
- The effect of endometriosis symptoms on absenteeism and presenteeism in the workplace and at home.J Manag Care Spec Pharm. 2017; 23: 745-754
- Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences.Hum Reprod. 2012; 27: 3412-3416
- Increased pressure pain sensitivity in women with chronic pelvic pain.Obstet Gynecol. 2013; 122: 1047-1055
- Assessing research gaps and unmet needs in endometriosis.Am J Obstet Gynecol. 2019; 221: 86-94
- Knowledge of, and treatment strategies for, endometriosis among general practitioners.Reprod Biomed Online. 2016; 32: 527-531
- Endometriosis education in schools: a New Zealand model examining the impact of an education program in schools on early recognition of symptoms suggesting endometriosis.Aust N Z J Obstet Gynaecol. 2017; 57: 452-457
Article info
Publication history
Footnotes
Disclosures: This study was funded by AbbVie, Inc. AbbVie sponsored the study; contributed to the design; participated in collection, analysis, and interpretation of data; and participated in writing, reviewing, and approval of the final version. Medical writing assistance was provided by Dr. Emily Mercadante of JK Associates, Inc., a member of the Fishawack Group of Companies, and was funded by AbbVie, Inc. Dr. Singh was a study investigator in therapeutic trials for endometriosis and fibroids sponsored by Allergan, AbbVie, and Bayer; and served as a speaker and advisor for Allergan, AbbVie, Bayer, Hologic, and Cooper Surgical. Dr. Soliman, Ms. Rahal, Ms. Robert, and Dr. Defoy are AbbVie employees and have stock or stock options. Dr. Nisbet is the president of One Research. Dr. Leyland has received grant support and lecture fees from AbbVie, Bayer, and Allergan and lecture fees from Johnson & Johnson.
All authors have indicated that they meet the journal's requirements for authorship.
Data, in part, were presented at the Fourth Annual Conference of the Canadian Society for the Advancement of Gynecologic Excellence (CanSAGE4), September 26–28, 2019, Ottawa, ON.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy